Alteogen Inc is a South Korea–based biopharmaceutical company specializing in biologics R&D and enabling technologies for large‑molecule medicines. The company develops biosimilars and “biobetter” formulations, as well as platforms that improve delivery and pharmacokinetics of therapeutic proteins and antibodies.
A core technology is its recombinant human hyaluronidase (also known as berahyaluronidase alfa/ALT‑B4), designed to facilitate high‑volume subcutaneous administration of biologics that are typically given intravenously. Alteogen also works on antibody–drug conjugate (ADC) technologies, long‑acting protein therapeutics, and ophthalmology and oncology biosimilar candidates. Its activities span protein engineering, cell line and process development, formulation science, and CMC analytics, with out‑licensing and collaborations with global pharmaceutical partners. The company is headquartered in Daejeon, South Korea.
None yet. When a new project in the record names Alteogen Inc as owner, partner or investor, it shows here.
First subcutaneous immune‑checkpoint inhibitor in Japan; can be given in as little as one minute and showed comparable exposure and response to IV pembrolizumab in a phase‑3 trial.
KEYTRUDA SC, a subcutaneous immune checkpoint inhibitor, is approved in Europe for faster administration across all adult indications.
KEYTRUDA QLEX, a subcutaneous immune checkpoint inhibitor, offers comparable efficacy to IV KEYTRUDA in treating metastatic NSCLC, with administration possible in one minute by healthcare providers.
CHMP backs KEYTRUDA SC for all EU adult indications and a new use in LA-HNSCC. Awaiting European Commission's final decision.
